HealthPolitics
BeOne, Hengrui top list of China’s most powerful drugmakers
Publication: STAT
Author: Damian Garde
Source published: 16/11/2026, 09:30:00 UTC
Briefing created: 16/11/2026, 10:05:19 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 16/11/2026, 09:36:25 UTC.
Briefings
STAT and WireScreen released China's Biotech Powerhouse 25, ranking 25 publicly traded firms in the country's drug industry. The ranking reflects firm value based on scientific strategy and market position. The list highlights a diverse landscape of companies founded between the 19th and 21st centuries, each navigating domestic scientific growth and geopolitical tensions.
Key points
- The ranking includes 25 publicly traded firms in China's drug industry, with values determined by scientific strategy and market position.
- Companies on the list span from firms founded in the 19th century to those established in the 21st century, reflecting the country's diverse biotech landscape.
Context
STAT and WireScreen published the ranking on November 16, 2026, to help policymakers and investors understand China's rapidly growing biotech sector amid domestic scientific renaissance and geopolitical standoff.
Limitations
The ranking covers only publicly traded firms; private companies are excluded. Data reflects firm value as of the publication date, which may not capture recent market shifts. The list does not include firms without public listings, limiting the scope to publicly traded entities.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 16/11/2026, 10:05:19 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiagdyw2uaptfvjzwuxnik4cag6vnzwshxrdpnjtt4rvbw7wgqqfim